An exploratory clinical trial about the efficacy and safety of GLP-1 receptor agonist dulaglutide in maintenance hemodialysis patients with type 2 diabetes treated with insuli
- Conditions
- End-stage renal disease caused by type 2 diabetes
- Registration Number
- JPRN-UMIN000024283
- Lead Sponsor
- iigata University Graduate School of Medical and Dental Sciences Department of Applied Molecular Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 14
Not provided
1. Those with hypersensitivity to DPP-4 inhibitors or GLP-1 receptor agonists 2. Those with serious diabetic ketosis, coma, or pre-coma 3. Those with severe active infection, serious trauma, or in the perioperative period 4. Those with severe heart or liver dysfunction 5. Those with problems shown as below: 1) Pituitary gland or adrenal gland dysfunction 2) In the status of impaired nutrition, starvation, irregular or insufficient dietary intake, or hyposthenia 3) Excessive muscular exercise 4) Heavy alcohol drinkers 6. BMI < 18.5 kg/m2 7. Those who are pregnant or beast-feeding, or those who might be pregnant 8. Those who are considered not eligible for this trial by attending doctors due to any medical reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method